Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
ID: 355182Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $450K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355182
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The funding opportunity, which will utilize the R34 activity code, is forecasted to have an award ceiling of $450,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter/Spring 2025. Interested applicants should prepare for a project start date anticipated for December 1, 2025, and can expect further details to be released in the upcoming synopsis.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin," aimed at funding fundamental research on skin injuries caused by chemical threats recognized as public health risks. The initiative seeks to enhance understanding of the mechanisms leading to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development, with a focus on examining two or more Chemicals of Concern, including at least one vesicant. This funding opportunity is crucial for advancing knowledge in the field of chemical threat response and wound healing, with an estimated funding amount of $1.25 million available for fiscal year 2025, allowing for up to five awards capped at $225,000 per year. Applications will open on January 16, 2025, and interested parties can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for NINR Resources and Related Research Projects in Firearm Injury Prevention (R24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for the NINR Resources and Related Research Projects in Firearm Injury Prevention, designated as an R24 grant, which does not allow clinical trials. This initiative aims to support research projects focused on preventing firearm injuries, encouraging collaborations among researchers to develop impactful proposals. With an estimated total program funding of $2 million and an award ceiling of $500,000, the anticipated synopsis will be posted on November 29, 2024, with applications closing on January 28, 2025, and awards expected to be made by July 1, 2025. Interested applicants are encouraged to prepare their proposals in advance of these dates.
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This initiative encourages research projects that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in studies that may identify common neuropsychiatric mechanisms across multiple conditions, although applications focusing on individual illnesses are also welcome. The NOFO is anticipated to be released in Fall 2024, with applications due in Winter 2025, and will utilize the R21 grant mechanism. Interested applicants should prepare for a project start date expected in December 2025, with further details to be outlined in the forthcoming announcement.